0.02 is only if this trial, with much higher doses is considered a failure (I don't think it will). Keep in mind the TBI trials effect on the accompanying concussion trial. Although Fragile X is on the opposite end of the spectrum, just as us investors see success in Rett as likely success in Fragile X, it could be reconsidered. A failure in Motiva and a flat outcome for 2566 would make funding for 2591 development difficult IMO. As we have seen historically, we get hammered on negative news and improve slightly on good news. Here's hoping the results are as outstanding as I hope them to be.
The prospect of Accelerated Approval, page-17
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.27 |
Change
-0.070(0.57%) |
Mkt cap ! $1.568B | |||
| Open | High | Low | Value | Volume |
| $12.30 | $12.40 | $12.16 | $2.116M | 172.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1925 | $12.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.36 | 1035 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |